Draft Genome Sequences of Four Strains of Campylobacter jejuni Isolated from Patients with Axonal Variant of Guillain-Barré Syndrome in Bangladesh

Hayat, Shoma; Nabila, Fahmida Habib; Asad, Asaduzzaman; Begum, Ruma; Jahan, Israt; Endtz, Hubert P.; Islam, Zhahirul

doi:10.1128/mra.01146-21

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To successfully invade the human intestine and cause disease, the ingestion of only a few hundred bacterial cells is sufficient to initiate the Campylobacter infection, with an incubation period that varies from 24 to 72 h before the onset of illness (Soro et al, 2020 ). Campylobacter- induced disease is usually followed by postacute infection sequelae such as bacteremia, urinary tract infections, sepsis, and complicated immune-mediated neuropathies (Hayat et al, 2022 ) (e.g., Guillain–Barré and Miller-Fisher syndromes). These neuropathies are characterized by neuromuscular paralysis (Itamura et al, 2022 ), posing significant human health risks (Balta et al, 2021b ; Elgamoudi and Korolik, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Anti-Campylobacter Probiotics: Latest Mechanistic Insights

Balta

Butucel

Ştef

et al. 2022

Foodborne Pathogens and Disease

View full text Add to dashboard Cite

The Campylobacter genus is the leading cause of human gastroenteritis, with the consumption of contaminated poultry meat as the main route of infection. Probiotic bacteria, such as Lactobacillus , Bacillus , Escherichia coli Nissle, and Bifidobacterium species, have a great immunomodulatory capacity and exhibit antipathogenic effects through various molecular mechanisms. Reducing Campylobacter levels in livestock animals, such as poultry, will have a substantial benefit to humans as it will reduce disease transmissibility through the food chain. Moreover, probiotic-based strategies might attenuate intestinal inflammatory processes, which consequently reduce the severity of Campylobacter disease progression. At a molecular level, probiotics can also negatively impact on the functionality of various Campylobacter virulence and survival factors (e.g., adhesion, invasion), and on the associated colonization proteins involved in epithelial translocation. The current review describes recent in vitro , in vivo , and preclinical findings on probiotic therapies, aiming to reduce Campylobacter counts in poultry and reduce the pathogen's virulence in the avian and human host. Moreover, we focused in particular on probiotics with known anti- Campylobacter activity seeking to understand the biological mechanisms involved in their mode of action.

show abstract